2. Signaling Pathways
  3. GPCR/G Protein
  4. LPL Receptor

LPL Receptor

Lysophospholipid Receptor

LPL Receptor

Related Products

PDF 1.08 MB

LPL Receptor (Lysophospholipid Receptor) group are members of the G protein-coupled receptor family of integral membrane proteins that are important for lipid signaling. In humans, there are eight LPL receptors, each encoded by a separate gene. These LPL receptor genes are also sometimes referred to as "Edg". LPL receptor ligands bind to and activate their cognate receptors located in the cell membrane. Depending on which ligand, receptor, and cell type is involved, the activated receptor can have a range of effects on the cell. These include primary effects of inhibition of adenylyl cyclase and release of calcium from the endoplasmic reticulum, as well as secondary effects of preventingapoptosis and increasing cell proliferation. Type: LPAR1, LPAR2, LPAR3, LPAR4, LPAR5, LPAR6, S1PR1, S1PR2, S1PR3, S1PR4, S1PR5.

LPL Receptor Isoform Specific Products:

LPL Receptor Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-11063S1
    Fingolimod-d4 hydrochloride
    		Antagonist ≥99.0%
    Fingolimod-d4 (hydrochloride) is the deuterium labeled Fingolimod hydrochloride. Fingolimod hydrochloride (FTY720) is a sphingosine 1-phosphate (S1P) antagonist with an IC50 of 0.033 nM in K562 and NK cells. Fingolimod hydrochloride (FTY720) also is a pak1 activator, a immunosuppressant.
    Fingolimod-d<sub>4</sub> hydrochloride
  • HY-RS12391
    S1PR1 Human Pre-designed siRNA Set A
    		Inhibitor

    S1PR1 Human Pre-designed siRNA Set A contains three designed siRNAs for S1PR1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
    S1PR1 Human Pre-designed siRNA Set A
    S1PR1 Human Pre-designed siRNA Set A
  • HY-RS12405
    S1pr5 Rat Pre-designed siRNA Set A
    		Inhibitor

    S1pr5 Rat Pre-designed siRNA Set A contains three designed siRNAs for S1pr5 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
    S1pr5 Rat Pre-designed siRNA Set A
    S1pr5 Rat Pre-designed siRNA Set A
  • HY-173322
    Lp(a)-IN-8
    		Inhibitor
    Lp(a)-IN-8 (compound 15) is an Lp(a) inhibitor. Lp(a) is a causal risk factor for atherosclerotic cardiovascular disease (ASCVD).
    Lp(a)-IN-8
  • HY-149004A
    SLF1081851 TFA
    		Inhibitor
    SLF1081851 (TFA) is a Spns2 inhibitor, inhibits S1P release (IC50=1.93 μM). SLF1081851 (TFA) plays a key role in development and immune system.
    SLF1081851 TFA
  • HY-157787
    Ginkgolic acid 2-phosphate
    		Agonist
    Ginkgolic acid 2-phosphate is a potent sphingosine 1-phosphate agonist. Ginkgolic acid 2-phosphate induces ERK phosphorylation. Ginkgolic acid 2-phosphate interactes with S1P1.
    Ginkgolic acid 2-phosphate
  • HY-145362
    S1P1 agonist 4
    		Modulator
    S1P1 agonist 4 has a better profile in both potency (EC50 < 0.05 mg/kg) and predicted human half-life (t1/2 ∼ 5 days).
    S1P1 agonist 4
  • HY-156408
    Spns2-IN-1
    		Inhibitor
    Spns2-IN-1 is a potent inhibitor of Spns2-dependent S1P transport (Spns2), with IC50 of 1.4±0.3 μM that plays an important role in immune response.
    Spns2-IN-1
  • HY-12355S
    Siponimod-d11
    		Modulator
    Siponimod-d11 is deuterium labeled Siponimod (HY-12355). Siponimod is an orally active and selective sphingosine-1-phosphate (S1P) receptor modulator. Siponimod is selective for S1P1 and S1P5 over S1P2, S1P3, and S1P4, with EC50s of 0.4, 0.98, >10000, >1000, and 750 nM, respectively. Siponimod can be used for multiple sclerosis (MS) research.
    Siponimod-d<sub>11</sub>
  • HY-173325
    LPA2 antagonist 6
    		Antagonist
    LPA2 antagonist 6 (example 2) is an antagonist of Lp(a). LPA2 antagonist 6 inhibits Lp(a) formation with an IC50 value of 2.33 nM. LPA2 antagonist 6 can be used in the research of cardiovascular disease.
    LPA2 antagonist 6
  • HY-W701470
    W140 hydrobromide
    		Antagonist
    W140 hydrobromide is a S1P1 antagonist with the Ki of 2.84 μM, and can enhanceof capillary leakage and restoration of lymphocyte egress.
    W140 hydrobromide
  • HY-159983
    GS-2278
    		Antagonist
    GS-2278 is an LPAR1 (lysophosphatidic acid receptor 1) antagonist with potential for research in idiopathic pulmonary fibrosis (IPF).
    GS-2278
  • HY-RS12395
    S1pr2 Mouse Pre-designed siRNA Set A
    		Inhibitor

    S1pr2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for S1pr2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
    S1pr2 Mouse Pre-designed siRNA Set A
    S1pr2 Mouse Pre-designed siRNA Set A
  • HY-144126
    S1P1 agonist 5
    		Agonist
    S1P1 agonist 5 is a selective and orally active S1P1 agonist. S1P1 agonist 5 inhibits the lymphocyte egress from the lymphoid tissue to the peripheral blood. S1P1 agonist 5 has the potential for the research of multiple sclerosis (MS).
    S1P1 agonist 5
  • HY-19511A
    GSK2018682 hydrochloride
    		Agonist
    GSK2018682 hydrochloride is an agonist for S1P1 and S1P5 receptor with pEC50s of 7.7 and 7.2, respectively, and has no agonist activity towards human S1P2, S1P3, or S1P4. GSK2018682 hydrochloride is used in the research of multiple sclerosis.
    GSK2018682 hydrochloride
  • HY-RS12404
    S1pr5 Mouse Pre-designed siRNA Set A
    		Inhibitor

    S1pr5 Mouse Pre-designed siRNA Set A contains three designed siRNAs for S1pr5 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
    S1pr5 Mouse Pre-designed siRNA Set A
    S1pr5 Mouse Pre-designed siRNA Set A
  • HY-119245
    Udifitimod
    		Modulator
    Udifitimod (BMS-986166) is a potent, selective and orally active S1P1R modulator. Udifitimod has the potential for the research of autoimmune diseases.
    Udifitimod
  • HY-125046
    CYM50374
    		Antagonist
    CYM50374 is a potent antagonist sphingosine-1-phosphate 4 (S1P4) antagonists, with the IC50 of 34 nM.
    CYM50374
  • HY-P991311
    GSK3178022
    		Inhibitor
    GSK3178022 is a human IgG1 monoclonal antibody (mAb) targeting LRP6. GSK3178022 inhibits the expression of WNT target genes SP5 and AXIN2. GSK3178022 has antitumor activity in the RSPO fusion model of colorectal cancer. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).
    GSK3178022
  • HY-16622A
    GSK 1842799 TFA
    		Modulator
    GSK1842799, an alkyl-substituted biaryl amino alcohol, is a selective S1P1 modulator developed for multiple sclerosis (MS). Upon phosphorylation, GSK1842799-P exhibited subnanomolar S1P1 agonist activity with over 1000-fold selectivity over S1P3. The compound showed good oral bioavailability, rapid in vivo conversion to GSK1842799-P, and significant lymphocyte count reduction at 0.1 mg/kg. It matched FTY720 efficacy at 3 mg/kg in the mouse EAE model and achieved comparable plasma levels to FTY-720 phosphate in cynomolgus monkeys. With favorable ADME, PK/PD properties, and toxicology, GSK1842799 advanced to further clinical development.
    GSK 1842799 TFA
Cat. No. Product Name / Synonyms Application Reactivity
LPL Receptor Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.